Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON20698Recruiting
Open-label trial of erlotinib and esomeprazole in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Erasmus MC. Primary endpoints: Erlotinib AUC with milk versus water without PPI and Erlotinib AUC with milk versus water with PPI. Started Dec 2016; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON20698.